Over ₹100 crore funding round to support growth in India and overseas markets.
India’s biotechnology sector has steadily evolved from a market focused largely on pharmaceuticals and diagnostics into one increasingly capable of developing advanced medical innovations. Among the most promising areas is cell and gene therapy, a field that is transforming cancer treatment globally.
Immuneel Therapeutics is positioning itself at the centre of that transformation.
The Bengaluru-based biotechnology company has raised more than ₹100 crore in a new Series B funding round, providing fresh momentum for its efforts to make advanced cancer therapies more accessible and affordable. The funding will support manufacturing expansion, commercialisation of its CAR-T therapy platform, and international growth across key global markets.
The round attracted participation from Singularity AMC, Rainmatter by Zerodha, and several high-net-worth investors, alongside continued backing from existing investors including Kiran Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital.
The investment reflects growing confidence in India’s ability to play a larger role in one of the most complex and rapidly advancing areas of modern medicine.
Building Advanced Cancer Treatments in India
Immuneel was founded with an ambitious vision.
The company aims to develop cell and gene therapies that can deliver world-class cancer treatment outcomes while addressing one of the industry’s biggest challenges: accessibility.
Globally, CAR-T therapies have shown remarkable results for certain blood cancers. However, treatment costs in Western markets often place these therapies beyond the reach of many patients. Manufacturing complexity, infrastructure requirements, and regulatory hurdles have traditionally limited widespread adoption.
Immuneel’s strategy focuses on developing these advanced therapies within India while significantly reducing treatment costs and expanding access.
The company’s founding team reflects the scale of that ambition. Immuneel was co-founded by biotechnology entrepreneur Kiran Mazumdar-Shaw, renowned physician and author Siddhartha Mukherjee, and healthcare investor Kush M. Parmar.
Their combined expertise across biotechnology, medicine, and healthcare innovation helped establish a platform designed to bring cutting-edge cancer treatment closer to patients who need it most.
The Growing Importance of CAR-T Therapy
CAR-T therapy represents one of the most significant breakthroughs in cancer treatment over the past decade.
Unlike conventional treatments that broadly target cancer cells, CAR-T therapy uses a patient’s own immune cells. These cells are collected, genetically modified to recognise cancer cells more effectively, and then reintroduced into the body to attack the disease.
The approach has demonstrated encouraging results for patients with certain forms of blood cancer who have exhausted other treatment options.
However, delivering these therapies at scale remains challenging.
Manufacturing requires highly specialised facilities, strict quality controls, and complex logistics. As a result, treatment costs in several developed markets can reach hundreds of thousands of dollars per patient.
Companies like Immuneel are attempting to change that equation by developing scalable manufacturing capabilities closer to emerging markets while maintaining international quality standards.
Expanding Manufacturing Capacity
A significant portion of the new funding will be directed toward expanding Immuneel’s GMP manufacturing infrastructure.
Good Manufacturing Practice facilities are essential for producing advanced cell therapies safely and consistently. Expanding manufacturing capacity allows the company to serve larger patient populations while supporting future product development efforts.
Manufacturing scale is particularly important in cell therapy because production capacity often becomes a limiting factor in patient access.
By strengthening its manufacturing capabilities now, Immuneel is preparing for both increased commercial demand and future clinical development programs.
The investment also positions the company to support additional therapies currently being developed within its broader pipeline.
Commercialising Qartemi
The funding will also support the continued commercialisation of Qartemi, Immuneel’s CAR-T therapy offering.
According to the company, the therapy has demonstrated that high-quality CAR-T treatment can be delivered at substantially lower costs than many comparable international alternatives.
CEO Amit Mookim described the commercialisation journey as proof that India can deliver advanced cell therapies while maintaining both quality and affordability.
For patients, affordability is not simply a pricing issue. It can determine whether treatment is accessible at all.
Reducing costs while maintaining clinical standards has become one of the defining challenges in advanced healthcare, particularly across emerging markets where demand often exceeds available resources.
Looking Beyond India
While India remains the company’s primary market, Immuneel’s ambitions extend well beyond national borders.
The latest funding will support expansion efforts across Asia-Pacific and the Middle East, regions where healthcare systems are increasingly investing in advanced cancer treatment capabilities.
The company is also pursuing clinical co-development partnerships in Australia and Southeast Asia.
These collaborations could help accelerate product development, broaden clinical evidence generation, and create additional pathways for international growth.
For Indian biotechnology companies, international expansion represents more than a commercial opportunity. It also signals the growing maturity of the country’s innovation ecosystem.
Historically, many advanced medical technologies were imported into India. Today, companies such as Immuneel are working to reverse that dynamic by developing globally competitive innovations within the country itself.
A Larger Vision for Healthcare Innovation
Kiran Mazumdar-Shaw has consistently advocated for making advanced healthcare technologies more accessible.
Her involvement in Immuneel reflects a broader belief that transformative medical innovation should not remain limited to a handful of countries or patient populations.
The company’s latest fundraising round strengthens its ability to pursue that vision.
By combining scientific research, manufacturing infrastructure, commercial execution, and international partnerships, Immuneel is attempting to create a sustainable platform for long-term growth in cell and gene therapy.
The opportunity extends beyond one company.
As India continues investing in biotechnology, advanced manufacturing, and healthcare innovation, successful examples can help establish the country as an important contributor to the future of global medicine.
What’s next
The next phase of growth for Immuneel will focus on execution.
Expanding manufacturing, scaling commercial operations, advancing its therapy pipeline, and entering new markets will require substantial investment and operational discipline.
The company now has additional resources to pursue those goals.
More importantly, it has growing investor confidence behind a mission that addresses one of healthcare’s most important challenges: making advanced therapies available to more patients.
As cell and gene therapy continues to reshape cancer treatment globally, Immuneel’s progress will be closely watched as a test of whether India can build internationally competitive biotechnology platforms while delivering meaningful improvements in affordability and access.
The latest funding round suggests many investors believe that the future is within reach.
Read more news, and follow us on Instagram
Kiran Mazumdar Shaw
